Skip to main content

Immunocore Holdings plc

corporate_fare Company Profile

Immunocore Holdings plc

IMCR·NASDAQ·Life Sciences·CIK 0001671927

We are a commercial stage biotechnology company that develops immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune diseases. We use our ImmTAX® (Immune mobilizing monoclonal TCRs Against X disease) platform to develop a range of products. In 2022, our main product, KIMMTRAK, received approval for treating unresectable or metastatic uveal melanoma ("mUM") from the FDA, the European Commission, and other health authorities. KIMMTRAK is approved in 39 countries and has been commercially launched in 30 countries, including the United States, Germany, and France. KIMMTRAK was the first approved therapy for mUM. We have treated over 2,000 cancer patients with KIMMTRAK (tebentafusp) and our other ImmTAX product candidates. Our clinical programs involve patients with various cancers, including melanoma, ovarian, lung, and colorectal. We are advancing three late-stage clinical programs within our ImmTAC® (Immune mobilizing monoclonal TCRs Against Cancer) portfolio, which includes KIMMTRAK and brenetafusp, which targets PRAME. KIMMTRAK is manufactured in Denmark and Germany, with final packaging in the Netherlands. We support KIMMTRAK's use in the United States and Europe with a commercial team that includes commercial, medical, sales, and value access members. We use a hybrid commercialization model with an in-house sales force in the United States and contracted resources in the United States and Europe.

Immunocore Holdings plc (NASDAQ:IMCR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for IMCR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for IMCR spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Brenetafusp-KIMMTRAK Combo Shows 70% Two-Year Survival in Metastatic Uveal Melanoma
  • Immunocore Q3: KIMMTRAK Sales $102.2M, Net Loss Widens to $14.2M, TEBE-AM Data Slips to Q2 2027
  • Immunocore Q3 Sales Dip to $102.2M; TEBE-AM Data Pushed to Q2 2027
  • KIMMTRAK Q3 Sales Slip to $102.2M as Net Loss Widens to $14.2M
  • Immunocore Completes Enrollment in Pivotal TEBE-AM Melanoma Trial, Data Expected by End of 2026

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$400.02M
Net Income
-$35.51M
Diluted EPS
-$0.71
Op. Cash Flow
-$10.71M
Free Cash Flow
-$15.05M
Gross Profit
$394.93M
Operating Income
-$45.35M
Cash & Equivalents
$467.71M
Debt / Equity
0.00×
Net Margin
-8.9%
Shares Outstanding
50.69M sh
Source: 10-K · filed 2026-02-25 · accession 0001671927-26-000005

Short Interest & Short Volume

14.21 days to cover

FINRA reported short interest of 7,793,995 shares in IMCR as of the October 30, 2026 settlement, a 0.1% decrease from the prior period — about 14.2 days to cover at its recent average daily volume. On November 20, 2026, 19.6% of IMCR volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)7,793,995 shares as of October 30, 2026
Change vs prior period▼ 0.1%
Days to cover14.21 at avg daily volume of 548,595
Daily short volume (FINRA facilities)19.6% of 346,122 shares on November 20, 2026
5-day average short volume32.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with I →
$26.41
52-week range · as of 2026-11-06 $26.41 – $40.71
Market cap
$1.36B
Volume
546.2K (1.1× avg)
3-mo avg 512.4K
Live data · 2026-11-22 12:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IMCR - Latest Insights

IMCR
Nov 06, 2026, 12:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $29.95
Real-time Price: $26.41 info
Change: -$3.54 (-12%) info
Market Cap: $1.364B info
IMCR
Nov 06, 2026, 9:01 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $27.70
Real-time Price: $26.41 info
Change: -$1.29 (-5%) info
Market Cap: $1.364B info
IMCR
Nov 06, 2026, 9:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $27.70
Real-time Price: $26.41 info
Change: -$1.29 (-5%) info
Market Cap: $1.364B info
IMCR
Nov 06, 2026, 9:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $28.40
Real-time Price: $26.41 info
Change: -$1.99 (-7%) info
Market Cap: $1.364B info
IMCR
Sep 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $32.60
Real-time Price: $26.41 info
Change: -$6.19 (-19%) info
Market Cap: $1.364B info
IMCR
Aug 06, 2026, 7:05 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $33.20
Real-time Price: $26.41 info
Change: -$6.79 (-20%) info
Market Cap: $1.364B info
IMCR
Aug 06, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $33.20
Real-time Price: $26.41 info
Change: -$6.79 (-20%) info
Market Cap: $1.364B info
IMCR
Aug 06, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $33.20
Real-time Price: $26.41 info
Change: -$6.79 (-20%) info
Market Cap: $1.364B info
IMCR
May 06, 2026, 7:09 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $29.30
Real-time Price: $26.41 info
Change: -$2.89 (-10%) info
Market Cap: $1.364B info
IMCR
May 06, 2026, 7:01 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $29.30
Real-time Price: $26.41 info
Change: -$2.89 (-10%) info
Market Cap: $1.364B info
IMCR
Feb 25, 2026, 7:01 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $33.00
Real-time Price: $26.41 info
Change: -$6.59 (-20%) info
Market Cap: $1.364B info
IMCR
Jan 30, 2026, 7:22 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $32.44
Real-time Price: $26.41 info
Change: -$6.03 (-19%) info
Market Cap: $1.364B info
IMCR
Jan 09, 2026, 7:11 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $33.10
Real-time Price: $26.41 info
Change: -$6.69 (-20%) info
Market Cap: $1.364B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets